International Journal of Current Research and Review
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Relation Between Exercise Performance and Blood Storage Condition and Storage Time in Autologous Blood Doping
biology Review Relation between Exercise Performance and Blood Storage Condition and Storage Time in Autologous Blood Doping Benedikt Seeger and Marijke Grau * Molecular and Cellular Sports Medicine, German Sport University Cologne, 50677 Cologne, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-221-4982-6116 Simple Summary: Autologous blood doping (ABD) refers to sampling, storage, and re-infusion of one’s own blood to improve circulating red blood cell (RBC) mass and thus the oxygen transport and finally the performance capacity. This illegal technique employed by some athletes is still difficult to detect. Hence knowledge of the main effects of ABD is needed to develop valid detection methods. Performance enhancement related to ABD seems to be well documented in the literature, but applied study designs might affect the outcome that was analyzed herein. The majority of recent studies investigated the effect of cold blood storage at 4 ◦C, and only few studies focused on cryopreservation, although it might be suspected that cryopreservation is above all applied in sport. The storage duration—the time between blood sampling and re-infusion—varied in the reported literature. In most studies, storage duration might be too short to fully restore the RBC mass. It is thus concluded that most reported studies did not display common practice and that the reported performance outcome might be affected by these two variables. Thus, knowledge of the real effects of ABD, as applied in sport, on performance and associated parameters are needed to develop reliable detection techniques. Abstract: Professional athletes are expected to continuously improve their performance, and some might also use illegal methods—e.g., autologous blood doping (ABD)—to achieve improvements. -
Impact of GH Administration on Athletic Performance in Healthy Young Adults: a Systematic Review and Meta-Analysis of Placebo-Controlled Trials MARK
Growth Hormone & IGF Research 34 (2017) 38–44 Contents lists available at ScienceDirect Growth Hormone & IGF Research journal homepage: www.elsevier.com/locate/ghir Review Article Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials MARK ⁎ Kasper Hermansena, , Mads Bengtsena, Michael Kjærb, Peter Vestergaardc,d, Jens Otto Lunde Jørgensena a Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark b Institute of Sports Medicine, Department of Orthopedic Surgery M, Bispebjerg Hospital and Centre for Healthy Aging, Faculty of Health and Medical Science, University of Copenhagen, Denmark c Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark d Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark ARTICLE INFO ABSTRACT Keywords: Objective: Illicit use of growth hormone (GH) as a performance-enhancing drug among athletes is prevalent, GH although the evidence of such effects in healthy, young subjects is sparse. We therefore performed a meta- Athletic performance analysis of published studies on the effect of GH administration on body composition, substrate metabolism, and Doping athletic performance in healthy, young subjects. Design: The English-language based databases PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were searched, and eligible articles were reviewed in accordance with the PRISMA guidelines. Fifty-four potentially relevant articles were retrieved of which 11 were included in this analysis comprising 254 subjects. Results: Administration of GH significantly increased lean body mass (p < 0.01) and decreased fat mass (p < 0.01). In addition, GH increased the exercising levels of glycerol (p = 0.01) and free fatty acids (p < 0.01), but did not alter the respiratory quotient during exercise (p = 0.30). -
Hormone Abuse in Sports: the Antidoping Perspective
Asian J Androl 2008; 10 (3): 391–402 DOI: 10.1111/j.1745-7262.2008.00402.x .Review . Hormone abuse in sports: the antidoping perspective Osquel Barroso, Irene Mazzoni, Olivier Rabin Science Department, World Anti-Doping Agency (WADA), Montreal, Quebec H4Z 1B7, Canada Abstract Since ancient times, unethical athletes have attempted to gain an unfair competitive advantage through the use of doping substances. A list of doping substances and methods banned in sports is published yearly by the World Anti- Doping Agency (WADA). A substance or method might be included in the List if it fulfills at least two of the following criteria: enhances sports performance; represents a risk to the athlete’s health; or violates the spirit of sports. This list, constantly updated to reflect new developments in the pharmaceutical industry as well as doping trends, enume- rates the drug types and methods prohibited in and out of competition. Among the substances included are steroidal and peptide hormones and their modulators, stimulants, glucocorticosteroids, β2-agonists, diuretics and masking agents, narcotics, and cannabinoids. Blood doping, tampering, infusions, and gene doping are examples of prohibited methods indicated on the List. From all these, hormones constitute by far the highest number of adverse analytical findings reported by antidoping laboratories. Although to date most are due to anabolic steroids, the advent of molecular biology techniques has made recombinant peptide hormones readily available. These substances are gradu- ally changing the landscape of doping trends. Peptide hormones like erythropoietin (EPO), human growth hormone (hGH), insulin, and insulin-like growth factor I (IGF-I) are presumed to be widely abused for performance enhancement. -
A Genealogy of Top Level Cycling Teams 1984-2016
This is a work in progress. Any feedback or corrections A GENEALOGY OF TOP LEVEL CYCLING TEAMS 1984-2016 Contact me on twitter @dimspace or email [email protected] This graphic attempts to trace the lineage of top level cycling teams that have competed in a Grand Tour since 1985. Teams are grouped by country, and then linked Based on movement of sponsors or team management. Will also include non-gt teams where they are “related” to GT participants. Note: Due to the large amount of conflicting information their will be errors. If you can contribute in any way, please contact me. Notes: 1986 saw a Polish National, and Soviet National team in the Vuelta Espana, and 1985 a Soviet Team in the Vuelta Graphics by DIM @dimspace Web, Updates and Sources: Velorooms.com/index.php?page=cyclinggenealogy REV 2.1.7 1984 added. Fagor (Spain) Mercier (France) Samoanotta Campagnolo (Italy) 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Le Groupement Formed in January 1995, the team folded before the Tour de France, Their spot being given to AKI. Mosoca Agrigel-La Creuse-Fenioux Agrigel only existed for one season riding the 1996 Tour de France Eurocar ITAS Gilles Mas and several of the riders including Jacky Durant went to Casino Chazal Raider Mosoca Ag2r-La Mondiale Eurocar Chazal-Vetta-MBK Petit Casino Casino-AG2R Ag2r Vincent Lavenu created the Chazal team. -
Olympic Doping
Even some Olympic athletes cheat with drugs | Science News for Students 3/16/20, 6:42 AM HEALTH & MEDICINE Even some Olympic athletes cheat with drugs As new ways of doping emerge, scientists develop ways to catch the cheaters Athletes train to get stronger, run faster and jump higher. But some may turn to an illegal short-cut: performance-enhancing drugs. Scientists are working to find these cheaters. JACOB AMMENTORP LUND/ISTOCKPHOTO By Sarah Zielinski August 15, 2016 at 6:00 am MANCHESTER, England — Keen viewers of the Rio Olympics this week may notice that one country’s team is a lot smaller than usual. Russia brought only about 70 percent of the athletes it had expected would compete. Some 30 percent — including all weightlifters and all but one track and field athletes — were banned from the competition. The reason? They were caught up in a cheating scandal. The type of cheating these athletes had participated in is known as “doping.” It involves the use of drugs to improve performance. These drugs have medical purposes for people who are ill. But in healthy athletes, they can provide an illegal advantage by boosting muscle growth or offering other benefits. And it’s not just using these substances that can get an athlete in trouble. Athletes also can get banned for refusing to participate in (or tampering with) efforts to find others who use doping drugs. The Russian scandal involved an elaborate plot to https://www.sciencenewsforstudents.org/article/even-some-olympic-athletes-cheat-drugs Page 1 of 5 Even some Olympic athletes cheat with drugs | Science News for Students 3/16/20, 6:42 AM interfere with these tests. -
Gene… Sport Science 14 (2020) Suppl 1: 18-23
Mazzeo, F., et al.: New technology and no drugs in sport: gene… Sport Science 14 (2020) Suppl 1: 18-23 NEW TECHNOLOGY AND NO DRUGS IN SPORT: GENE DOPING REGULATION, EDUCATION AND RESEARCH Filomena Mazzeo1 and Antonio Ascione2 1Department of Sport Sciences and Wellness, Parthenope University, Naples, Italy 2University of Bari “Aldo Moro”, Italy Review paper Abstract This article examines the current state of genetic doping, the use of gene therapy in sports medicine, and the ethics of genetic improvement. The purpose of gene therapy is to use the foundations of genetic engineering for therapeutic use. Gene doping is a expansion of gene therapy. Innovative research in genetics and genomics will be used not only to diagnose and treat disease, but also to increase endurance and muscle mass. The first genetic therapy tests were conducted with proteins closely related to doping (e.g. erythropoietin and growth hormone). The World Anti-Doping Agency (WADA), an international organization created in 1999 to "promote, coordinate, and monitor the fight against doping in sport in all its forms," defines gene doping as the "nontherapeutic use of cells, genes, genetic elements, or modulation of gene expression, having the capacity to enhance performance" (World Anti-Doping Agency, 2008). This method represents a new Technology, but not devoid of adverse and fatal effects; gene doping could be dangerous for the athlete. The use of the athlete's biological-molecular passport represents a possible preventive and precautionary anti-doping strategy. The best way to prevent gene doping is a combination of regulation, education, research and the known of health risks. -
Development of Doping in Sports: Overview and Analysis
Journal of Physical Education and Sport ® (JPES), 18(3), Art 244, pp. 1669 - 1677, 2018 online ISSN: 2247 - 806X; p-ISSN: 2247 – 8051; ISSN - L = 2247 - 8051 © JPES Original Article Development of Doping in sports: overview and analysis FILOMENA MAZZEO1, GAETANO ALTAVILLA2, FRANCESCA D’ELIA3, GAETANO RAIOLA3 1Department of Science and Technology University of Naples “Parthenope”, Naples, ITALY 2Faculty of Kinesiology, University of Split, Split CROATIA 3Department of Human Philosophical and Education sciences, University of Salerno, ITALY Published online: September 30, 2018 (Accepted for publication August 10, 2018) DOI:10.7752/jpes.2018.03244 Abstract: Doping is a public health issue and not simply a problem inside the professional sports community It is a complex and ancient phenomenon considering the vast variety of substances, supplied through both legal and illegal trading routes. It occurs in elite athletes but also affects amateur athletes and was generally considered as dangerous and unhealthy. Furthermore, it involves athletes’ friends and relatives, medical staff, managers, chemists, biologists and pharmacists, pharmaceutical industries, clandestine laboratories and criminal organizations. Over time, doping has shown a great ability to discover and always use new substances and appropriated the new scientific discoveries. Unfortunately, new discoveries for the human health are been used in distorted way by the athletes. In fact, the athletes may be able to use gene therapy to re-engineer their bodies for better performances. Drug dependence depends on several factors: the socio-environmental context of the subject and what effects have the substance in the body. We will agree that sport is essentially under the current anti-doping campaign executed by a coordinated alliance between the World Anti-Doping Agency (WADA), law enforcement authorities, sports organizers and the media. -
Dream-April-2017-Eng
R.N. 70269/98 Postal Registration No.: DL-SW-1/4082/15-17 ISSN : 0972-169X Date of posting: 26-27 of advance month Date of publication: 24 of advance month April 2017 Vol. 19 No. 7 Rs. 5.00 MEMO: Mass Extinction Memorial Observatory Global Monument in Memory of Extinct Species Editorial: Please do not 35 trivialise science communication MEMO: Mass Extinction Memorial 34 Observatory – Global Monument in Memory of Extinct Species Keeping Sports Clean : A cat- 32 and-mouse game Extremely Drug Resistant 30 Tuberculosis Coconut: A Wonder food 29 History of Medicine in India 27 Safeguarding against Rabies— 24 the 1-2-3 of post-exposure treatment Recent developments 21 in science and technology 36 Editorial Please do not trivialise science communication Dr. R. Gopichandran Let me argue for the cause of science communication. Science opportunities to enhance them to help deliver appropriate information communicators are embedded in the cause. Any good for the cause in a timely manner: and (III) Create interest to perceive and interpret will mean good for people engaged in it; almost Samaritans in this credibility of messages delivered. This bottom-up stakeholder case. How often do we come across proofs/empirically evidenced engagement can be expected to create critical groundswell to tackle cause-effect relationships pertaining to science communication? challenges due to multiple anachronisms that tend to plague the When will we get to see a steep rise in the spread and depth of case message – intent – impact link. examples that demonstrate the holistic value of communication? Scale of operations is equally important. -
<Vorname> <Nachname>
To the INTERNATIONAL SKI FEDERATION - Members of the FIS Council Blochstrasse 2 - National Ski Associations 3653 Oberhofen/Thunersee - Committee Chairwomen/Chairmen Switzerland Tel +41 33 244 61 61 Fax +41 33 244 61 71 Oberhofen, 4th June 2019 Summary of the FIS Council Meeting, 2nd June 2019, Cavtat-Dubrovnik (CRO) Dear Mr. President, Dear Ski Friends, In accordance with art. 32.2 of the FIS Statutes we have pleasure in sending you the Summary of the most important decisions from the FIS Council Meeting which took place on 2nd June 2019 in Cavtat-Dubrovnik (CRO). 1. Members present The following elected Council Members were present at the meeting in Cavtat- Dubrovnik (SUI) on Sunday, 2nd June 2019: President Gian Franco Kasper, Vice-Presidents Mats Arjes, Janez Kocijancic, Aki Murasato and Patrick Smith, Members: Andrey Bokarev, Steve Dong Yang, Dean Gosper, Alfons Hörmann, Hannah Kearney (Athletes’ Commission Representative), Roman Kumpost, Dexter Paine, Flavio Roda, Erik Roeste, Konstantin Schad (Athletes’ Commission Representative), Peter Schröcksnadel, Martti Uusitalo (by ‘phone), Eduardo Valenzuela and Michel Vion. Secretary General Sarah Lewis 2. Minutes from the Council Meeting in Oberhofen (SUI) November 2019 With the inclusion of a correction in the report on Tokyo 2020 (reference to currency Japanese yen instead of US dollars) requested by Vice-President Aki Murasato, the minutes from the Council Meeting in Oberhofen (SUI) from 16th November 2018 and the Gathering in Åre (SWE) from 13th February were approved. 3. The FIS World -
Coordinating Investigations and Sharing Anti-Doping Information and Evidence
Coordinating Investigations and Sharing Anti-Doping Information and Evidence May 2011 1. Introduction 1.1 Based on experience gained, evidence gathered, and lessons learned in the first ten years of its existence, it is WADA’s firm view that, to succeed in the fight against doping in sport, and so to protect the rights of clean athletes everywhere, Anti-Doping Organizations need to move beyond drug-testing alone to develop additional ways of gathering, sharing and exploiting information and evidence about the supply to and use of prohibited substances and methods by athletes under their jurisdiction. 1.2 While drug-testing will always remain an important part of the anti- doping effort, it is not capable on its own of uncovering and establishing most of the anti-doping rule violations in the World Anti- Doping Code that Anti-Doping Organizations must investigate and pursue. In particular, while the violations of presence and use of prohibited substances and methods can be uncovered by laboratory analysis of urine and blood samples collected from athletes, other anti- doping rule violations such as possession or administration of or trafficking in prohibited substances or methods can only be effectively identified and pursued through the collection of ‘non-analytical’ anti- doping information and evidence. 1.3 This means new investigative methods and techniques have to be deployed, and new partnerships have to be forged, particularly between the sports movement and public authorities engaged in the broader fight against doping in society. These new partnerships will allow Anti-Doping Organizations to take advantage of the investigative powers of those public authorities, including search and seizure, surveillance, and compulsion of witness testimony under penalties of perjury. -
Gene Doping Detection Based on Polymerase Chain Reaction (PCR)
Laboratory Guidelines Gene Doping Detection based on Polymerase Chain Reaction (PCR) Version 1.0 January 2021 TABLE OF CONTENTS 1.0 Objective ......................................................................................................................... 3 2.0 Scope .............................................................................................................................. 3 3.0 Introduction .................................................................................................................... 3 4.0 Test Requirements ........................................................................................................ 3 4.1. Test Method Validation Requirements ..................................................................................... 3 4.2. Test Method Accreditation Requirements ................................................................................ 4 4.3. Pre-analytical Procedure ......................................................................................................... 4 4.4. Analytical Testing Procedure ................................................................................................... 5 4.4.1. Initial Testing Procedure (ITP) .......................................................................................... 5 4.4.2. Confirmation Procedures (CPs) ........................................................................................ 6 5.0 Interpretation and Reporting of Results ..................................................................... -
What Doctors and Scientists Are Saying About Human Growth Hormone in the Year 2003
What Doctors and Scientists Are Saying About Human Growth Hormone in the Year 2003. TABLE OF CONTENTS H1 Disclaimer H2 Introduction H3 A String of Successes H3_1 A simple description of the growth hormone system. H3_2 Growth hormone treatment of growth hormone deficiency in children. H3_3 Growth hormone treatment of growth hormone deficiency in adults. H3_4 Growth hormone treatment of children and adults with kidney failure. H3_5 Growth hormone and Prader-Willi syndrome. H3_6 Growth hormone and cystic fibrosis. H3_7 Human growth hormone and Turner Syndrome. H3_8 Growth hormone and severe burns. H3_8_1 The metabolic consequences of severe burns. H3_8_2 The benefits of growth hormone therapy for burns H3_8_3 The disadvantages of growth hormone treatment for burns. H3_8_4 Drug combinations may bring burn therapy progress. H3_9 Growth hormone can reduce wasting in critically ill patients. H3_10 The effects of axis hormones on skin and wound healing. H3_11 Growth hormone therapy in HIV-infected patients. H3_12 Conclusions about hGH-responsive medical conditions. H4 A Promising Disappointment: Growth Hormone and Ageing. H4_1 Ageing, bone strength and growth hormone. H4_2 Age, muscle loss (sarcopenia) and growth hormone. H4_2_1 A description of age-related sarcopenia H4_2_2 The causes of age-related sarcopenia. H4_2_3 Exercise is the best antidote to sarcopenia. H4_2_4 Growth hormone may modestly increase muscular strength in the elderly. H4_2_5 Growth hormone increases lean mass, but the benefit is uncertain. H4_2_6 Innervation changes may enhance muscle strength. H4_2_7 Growth hormone resistance. H4_2_8 Exercise induces growth hormone. H4_2_9 Obesity decreases growth hormone secretion. H4_2_10 Locally produced IGF-I may dominate age-related sarcopenia H4_2_11 GH inducers can strengthen muscles in the elderly.